ArkBio Completes Phase I Dosing of AK0406 Influenza Drug
SHANGHAI, July 23, 2026 ArkBio has successfully completed dosing across all cohorts in its Australian Phase I clinical trial...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SHANGHAI, July 23, 2026 ArkBio has successfully completed dosing across all cohorts in its Australian Phase I clinical trial...
VALBY, Denmark, July 23, 2026 Lundbeck has received U.S. Food and Drug Administration (FDA) Fast Track designation for Lu...
NEW YORK, July 22, 2026 Royalty Pharma plc has announced the acquisition of a portion of Neurimmune’s royalty interest...
